Breast Neoplasm Clinical Trial
Official title:
Pre-habilitation Program for Women Indicated to Breast Cancer Surgical Treatment.
The National Cancer Institute estimated 625 thousand new cases of cancer (excluding cases of non-melanoma skin cancer) in Brazil for each year between 2020-2022. In 2018, there were 2.1 million new cases of breast cancer in the world, being the first in the ranking of cancers in women. Practices in healthy eating and exercise can protect and / or decrease the risk of breast cancer and improve treatment results. Breast cancer treatments cause cardiovascular changes due to age-related factors, pre-existing chronic diseases and comorbidities such as obesity, smoking and dyslipidemia. Obesity is associated with the development of several types of cancer, including breast cancer. Therapies for breast cancer have a strong association with impaired cardiac function, ranging from permanent, transient cardiotoxic effects and changes in lipid metabolism. In addition to the cardiotoxic effects, the pathophysiology of cancer and treatment favor the appearance of muscle changes, such as sarcopenia. There is sufficient evidence to support that exercise improves fitness before, during and after the completion of cancer treatment. Pre-qualification in cancer treatment is an opportunity to increase physiological reserves before neoadjuvant therapies or surgery, with the intention of improving results and accelerating recovery. It can be composed of physical exercises, nutritional interventions, and psychosocial. Excess weight or depletion are factors that negatively influence surgical and cancer outcomes. In view of the evidence, the aim of this project is to evaluate the effectiveness of physical exercise in a surgical pre-habilitation program for women diagnosed with breast cancer undergoing cancer treatment with a curative therapeutic proposal at the National Cancer Institute in Rio de Janeiro. This is a randomized clinical trial, where patients will be randomly allocated to the Intervention Group and the Control Group. The patients in the intervention group will be instructed to practice physical exercises at home until the date of surgery and those in the control group will only be instructed to maintain their usual activities. All patients will be guided individually by a nutritionist with a view to a healthier nutritional status and control of comorbidities.
Status | Recruiting |
Enrollment | 248 |
Est. completion date | December 30, 2023 |
Est. primary completion date | December 30, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion criteria: - have a diagnosis of breast cancer and indication for cancer treatment with a curative therapeutic proposal Exclusion criteria: - having a previous cancer diagnosis - staging IV - practitioner of physical exercise at least 90 minutes per week - not being able to answer the questionnaires - be unable to practice unsupervised exercises for any reason, including: dysfunctionss orthopedic, neurological, decompensated cardiorespiratory and severe renal. |
Country | Name | City | State |
---|---|---|---|
Brazil | Instituto Nacional do Câncer / HCIII | Rio De Janeiro |
Lead Sponsor | Collaborator |
---|---|
Instituto Nacional de Cancer, Brazil |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in functional capacity and muscle strength - dynamometry assessment using handgrip strength | The handgrip strength will be assessed using the Kratos dynamometer (model ZM - manual, Brazil). During the execution of the grasping movement, the patients are positioned seated with the adducted arm parallel to the trunk, shoulder in neutral rotation and elbow flexed at 90 °. Three measurements are made, with a minimum interval of 30 seconds between them, and the highest value obtained is considered. | Inclusion, post chemotherapy, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Primary | Changes in functional and cardiopulmonary capacity - evaluation of the 6-minute walk test | The six-minute walk test will be performed in a 20-meter flat corridor, with previously demarcated distances, following the recommendations of the American Thoracic Society. Monitoring of blood pressure (BP), heart rate (HR), partial oxygen saturation (SpO2) and BORG effort perception scale will be performed before, during and after the test. For the collection of HR and SpO2 the pulse oximeter G-TECH model LED (MD 300C19) will be used and for blood pressure measurement the sphygmomanometer Heidji. | Inclusion, post chemotherapy, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Primary | Changes cardiopulmonary capacity - evaluation of the cardiac autonomic modulation through heart rate variability. | It will be evaluated through the collection of HRV. Data will be extracted via Polar V800. | Inclusion, post chemotherapy, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Primary | Changes in Sarcopenia - muscle strength and performance assessment using Time Up and Go Test | Individuals will be asked to get up from a standard chair, walk to a marker 3 meters away and return the chair, sitting down again. The time spent will be measured with a stopwatch. | Inclusion, post chemotherapy, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Primary | Changes in Sarcopenia - muscle strength and performance assessment using SARC-F questionnaire | The questionnaire consists of 5 questions for the assessment of muscle strength limitations, the ability to walk, get up from a chair, up and down stairs and experiences with falls, used to assess physical performance in sarcopenia. In 2016, a change in this questionnaire was suggested, in addition to the questions, adding the calf circumference measurement.Such an evaluation will be performed by adopting the measurement of the largest perimeter (maximum measurement in the plane perpendicular to the longitudinal line of the calf) with the patient sitting with the knees and ankles flexed at an angle of ninety degrees and feet 20 cm apart from each other using an inextensible tape ( Sanny®, model TR-4010, Brazil). The measuring tape will be passed along the entire length of the calf in an adjusted manner, but without compressing the skin. The measurements will be recorded in the nearest cm. | Inclusion, post chemotherapy, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Primary | Changes in Sarcopenia - Evaluation of the corrected arm muscle area | To calculate this measure, the equations proposed by Heymsfield will be used, according to gender, using in the formula the triciptal skin fold. | Inclusion, post chemotherapy, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Primary | Changes in functional and cardiopulmonary capacity - evaluation of the 6-minute step test | The six-minute step test will be performed with a step measuring 17 cm in height, 80 cm in width and 30 cm in length, following the same recommendations of the American Thoracic Society to the six-minute walk test. The patient must go up and down the steps for 6 minutes and the evaluator must have at the end of the test the total amount of ups and downs performed. Monitoring of blood pressure (BP), heart rate (HR), partial oxygen saturation (SpO2) and BORG effort perception scale will be performed before, during and after the test. For the collection of HR and SpO2 the pulse oximeter G-TECH model LED (MD 300C19) will be used and for blood pressure measurement the sphygmomanometer Heidji. | Inclusion, post chemotherapy, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Secondary | Changes in Nutritional Risk | Evaluation through the Global Subjective Assessment Produced by the Patient (ASG-PPP). | Inclusion and pre-surgical moment | |
Secondary | Changes in Fatigue | Evaluation through the FACIT-Fatigue 4th version Questionnaire (Functional Assessment of Chronic Illness Therapy-Fatigue) | Inclusion, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Secondary | Changes in Physical activity level | Evaluation through the International Physical Activity Questionnaire (IPAQ) - short version. | Inclusion, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Secondary | Changes in Health-related quality of life | Evaluation through the EORTC QLQ-C30 3rd version | Inclusion, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Secondary | Assessment of adherence to physical exercises | Through the exercise diary, in which group A patients will be instructed to fill it out daily during the intervention period. In this diary, patients must inform the types of exercises performed each day, as well as the degree of difficulty and intensity. | pre-surgical moment | |
Secondary | Assessment of behavioral change in physical exercise | Evaluation through the International Physical Activity Questionnaire - long version. | pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Secondary | Evaluation of the patients' perception regarding the performance of the exercises | For the intervention group, at the time of the post-intervention assessment, a questionnaire will be applied with 15 pre-established questions about the experience regarding the educational material received, as well as regarding the performance of the exercises. The professional who will ask the questions in this questionnaire will not be the same person who carried out the guidelines and made the weekly phone calls, so that there is no bias in the answers. | pre-surgical moment | |
Secondary | Changes in alcohol consumption and smoking | Evaluation through the Behavioral Risk Factor Surveillance System - BRFSS questionnaire | Inclusion, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Secondary | Changes in anthropometric data through body weight assessment | For the measurement of body weight, the patient will be instructed to stand up right, in the center of the scale, without shoes and wearing light clothing. You will be asked to distribute your body weight evenly over your feet. The scale used will be a portable digital type (Welmy®, model 110, Brazil), with a maximum capacity of 150 (kilogram; Kg) and accuracy of 100 (gram; g) | Inclusion, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. | |
Secondary | Evaluation of anthropometric data by height | To measure the height (meter; m), a measuring tape fixed on the wall will be used. The measurement will be performed with the patient standing, barefoot or wearing thin stockings, and with as little clothing as possible so that the position of the body can be seen by the examiner. He will be instructed to stand in an orthostatic position looking at a fixed point at eye level (Frankfurt horizontal plane), to distribute the weight equally between both feet and to keep the arms freely loose along the trunk, with the palms facing the thighs. | Inclusion | |
Secondary | Changes in anthropometric data through tricipital skin fold assessment | For measurement, the fatty tissue will be slightly detached from the muscle tissue and clamped with the calibrator forming a right angle exactly at the marked location. The arm should be kept relaxed and released at the side of the body during the measurement. The measurement will be determined parallel to the longitudinal axis of the dominant arm, and there may be changes with the appearance of some postoperative complication in the limb to be evaluated, on the posterior face, with the exact point of repair being the distance between the acromion and the olecranon, following the same technique described for BP measurement. | Inclusion, pre-surgical moment, 30 days after surgery, 6 months after surgery and 1 year after surgery. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03273426 -
Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.
|
N/A | |
Recruiting |
NCT04583124 -
Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)
|
N/A | |
Active, not recruiting |
NCT04489173 -
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT02913573 -
Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction
|
Phase 2 | |
Completed |
NCT03124095 -
Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer
|
N/A | |
Terminated |
NCT00251095 -
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT05576545 -
Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment
|
N/A | |
Active, not recruiting |
NCT03625635 -
Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment
|
N/A | |
Recruiting |
NCT04799535 -
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
|
||
Withdrawn |
NCT03266562 -
Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography
|
N/A | |
Completed |
NCT00530868 -
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
|
Phase 2 | |
Recruiting |
NCT06255808 -
Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
|
||
Completed |
NCT04640220 -
Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors
|
N/A | |
Completed |
NCT02970682 -
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02316561 -
Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer
|
N/A | |
Terminated |
NCT00638963 -
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
|
Phase 2 | |
Terminated |
NCT00249301 -
A Study of MLN8054 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06056414 -
Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation
|
N/A | |
Recruiting |
NCT05427071 -
Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy
|
N/A | |
Recruiting |
NCT03740893 -
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
|
Phase 2 |